Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
DAYVIGO
Generic name / active ingredient
lemborexant
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-30

Copy from the pack in hand

Source-linked reading points

  • The pack mg identifies strength and is not a tablet count. U.S. and Japanese strengths and label wording differ; this site does not generate an individual tablet count, timing or missed-use action from age, insomnia duration or market.
  • Lemborexant can affect next-day alertness, attention, driving and motor coordination. If an older adult remains markedly drowsy, unsteady on standing or has a fall, do not drive, operate hazardous equipment, add another sleep medicine or use alcohol; seek timely professional review.
  • Sleep-walking, sleep-driving, eating, making calls or other activities while not fully awake are complex-sleep-behaviour warnings. Secure safety and contact the prescriber immediately; injury, altered awareness, breathing difficulty or another acute danger requires local emergency support.
  • Sleep paralysis, hallucination-like experiences around sleep or waking, or temporary leg weakness should be recorded with timing and co-medications and reviewed professionally. The site cannot diagnose from these events or direct an individual increase, decrease or stop.

Reviewed presentation examples — compare every field

  • Lemborexant 5 mg per tablet; 30-tablet bottleNDC 62856-405-30
  • Lemborexant 5 mg per tablet; 90-tablet bottleNDC 62856-405-90
  • Lemborexant 10 mg per tablet; 30-tablet bottleNDC 62856-410-30
  • Lemborexant 10 mg per tablet; 90-tablet bottleNDC 62856-410-90
  • Lemborexant 2.5 mg per tablet; Japanese PMDA product identityPMDA 30200AMX00017000
  • Lemborexant 5 mg per tablet; Japanese PMDA product identityPMDA 30200AMX00018000
  • Lemborexant 10 mg per tablet; Japanese PMDA product identityPMDA 30200AMX00019000

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-30
Source record
8 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image